Cardiovascular disease and subsequent kidney disease

被引:197
作者
Elsayed, Essam F.
Tighiouart, Hocine
Griffith, John
Kurth, Tobias
Levey, Andrew S.
Salem, Deeb
Sarnak, Mark J.
Weiner, Daniel E.
机构
[1] Tufts Univ New England Med Ctr, Dept Med, Div Nephrol, Boston, MA 02111 USA
[2] Tufts Univ New England Med Ctr, Dept Med, Div Cardiol, Boston, MA 02111 USA
[3] Tufts Univ New England Med Ctr, Biostat Res Ctr, Boston, MA 02111 USA
[4] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA
关键词
D O I
10.1001/archinte.167.11.1130
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Chronic kidney disease is a risk factor for cardiovascular disease ( CVD); however, it is uncertain if CVD is a risk factor for progression or development of kidney disease. Methods: Individual patient data were pooled from 2 longitudinal, community-based, limited-access studies, the Atherosclerosis Risk in Communities Study and the Cardiovascular Health Study. Baseline CVD was defined by stroke, angina, claudication, transient ischemic attack, coronary angioplasty or bypass, and recognized or silent myocardial infarction. Study outcomes included kidney function decline, defined by an increase in serum creatinine level of at least 0.4 mg/dL ( >= 35.4 mu mol/L), and development of kidney disease, defined by an increase in serum creatinine level of at least 0.4 mg/dL ( >= 35.4 mu mol/L) in which the baseline serum creatinine level was less than 1.4 mg/dL ( < 123.8 mu mol/L) in men and less than 1.2 mg/dL ( < 106.1 mu mol/L) in women and the final serum creatinine levels exceeded these levels. Secondarily, kidney function decline was defined by an estimated glomerular filtration rate ( eGFR) reduction of at least 15 mL/min per 1.73 m(2), and development of kidney disease was defined by an eGFR reduction of at least 15 mL/min per 1.73 m(2) in which the baseline eGFR was at least 60 mL/min per 1.73 m(2) and the final eGFR was below these levels. Multivariate logistic regression analysis was used to determine the association between CVD and outcomes. Results: Among 13 826 individuals, the mean +/- SD baseline serum creatinine level was 0.9 +/- 0.2 mg/dL ( 79.6 +/- 17.7 mu mol/L), and the mean +/- SD baseline eGFR was 89.8 +/- 20.1 mL/min per 1.73 m(2). In serum creatinine level-based models, 520 individuals ( 3.8%) experienced kidney function decline, and 314 individuals ( 2.3%) developed kidney disease during a mean +/- SD of 9.3 +/- 0.9 years of follow-up. Baseline CVD, present in 1787 individuals ( 12.9%), was associated with an increased risk of all outcomes ( odds ratio, 1.70; 95% confidence interval, 1.36-2.13), an odds ratio of 1.75 ( 95% confidence interval, 1.32-2.32) for serum creatinine level, and odds ratios of 1.28 ( 95% confidence interval, 1.13-1.45) and 1.54 ( 95% confidence interval, 1.26-1.89) for eGFR for kidney function decline and development of kidney disease, respectively. Conclusion: Cardiovascular disease is independently associated with kidney function decline and with the development of kidney disease.
引用
收藏
页码:1130 / 1136
页数:7
相关论文
共 25 条
[1]   Associations between retinal microvascular abnormalities and declining renal function in the elderly population: The Cardiovascular Health Study [J].
Edwards, MS ;
Wilson, DB ;
Craven, TE ;
Stafford, J ;
Fried, LF ;
Wong, TY ;
Klein, R ;
Burke, GL ;
Hansen, KJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (02) :214-224
[2]   K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword [J].
Eknoyan, G ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :S14-S266
[3]   Predictors of new-onset kidney disease in a community-based population [J].
Fox, CS ;
Larson, MG ;
Leip, EP ;
Culleton, B ;
Wilson, PWF ;
Levy, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (07) :844-850
[4]  
Fried Linda P., 1991, Annals of Epidemiology, V1, P263
[5]   Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I [J].
Garg, AX ;
Clark, WF ;
Haynes, RB ;
House, AA .
KIDNEY INTERNATIONAL, 2002, 61 (04) :1486-1494
[6]   Projecting the number of patients with end-stage renal disease in the United States to the year 2015 [J].
Gilbertson, DT ;
Liu, JN ;
Xue, JL ;
Louis, TA ;
Solid, CA ;
Ebben, JP ;
Collins, AJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (12) :3736-3741
[7]   Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J].
Go, AS ;
Chertow, GM ;
Fan, DJ ;
McCulloch, CE ;
Hsu, CY .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) :1296-1305
[8]   Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial [J].
Gouva, C ;
Nikolopoulos, P ;
Ioannidis, JPA ;
Siamopoulos, KC .
KIDNEY INTERNATIONAL, 2004, 66 (02) :753-760
[9]   Progression of chronic kidney disease: Can it be prevented or arrested? [J].
Jaber, BL ;
Madias, NE .
AMERICAN JOURNAL OF MEDICINE, 2005, 118 (12) :1323-1330
[10]   Blood pressure and end-stage renal disease in men [J].
Klag, MJ ;
Whelton, PK ;
Randall, BL ;
Neaton, JD ;
Brancati, FL ;
Ford, CE ;
Shulman, NB ;
Stamler, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :13-18